Sucampo Announces First Quarter 2017 Earnings Call
April 19 2017 - 6:30AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that it will host its
first quarter 2017 financial results teleconference and webcast at
8:30 a.m. Eastern on Wednesday, May 3rd. The press release
announcing the financial results and operating highlights is
expected to be released before the opening of capital markets that
day.
Individuals interested in accessing the live
audio webcast of the teleconference may do so at
http://www.sucampo.com/investors/events-presentations/ and should
log on 10 to 15 minutes before the teleconference begins to
download any software required. Presentation slides will be
available via the webcast link. A replay of the webcast will also
be available on Sucampo’s website for several days after the live
event. Alternatively, individuals may dial 888-636-8238 (domestic)
or 484-747-6635 (international) and use passcode 8878999. A replay
of the teleconference will be available by dialing 855-859-2056
(domestic) or 404-537-3406 (international), passcode 8878999,
approximately two hours after the teleconference concludes. The
archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of specialized medicines that meet major unmet
medical needs of patients worldwide. Sucampo has two marketed
products – AMITIZA, its lead product, and RESCULA – and a
late-stage pipeline of product candidates in clinical development
for orphan disease areas. VTS-270 is a mixture of
2-hydroxypropyl-B-cyclodextrins with a specific compositional
fingerprint that has been granted orphan designation in the U.S.
and Europe and is in a pivotal Phase 2/3 clinical trial for the
treatment of Niemann-Pick Disease Type C-1. Sucampo has an
option for the North American rights to CPP1-x/sulindac, which is
in Phase 3 development for the treatment of familial adenomatous
polyposis and has been granted orphan drug designation in the
U.S. A global company, Sucampo is headquartered in Rockville,
Maryland, and has operations in Japan and Switzerland. For more
information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024